Advancing Patient-Centric Drug Delivery for Neurodegenerative Disease with Orally Dissolving Tablets
Summary: In the evolving landscape of patient-centric drug development, innovators are increasingly prioritizing patient-friendly dosage forms from the early stages of drug design. Patient acceptability and preference are critical considerations for ensuring therapeutic effectiveness. As the global population ages, the prevalence of dysphagia, or difficulty in swallowing, has risen, especially among individuals with neurodegenerative conditions like Alzheimer’s, Parkinson’s, and ALS. Read this article to learn how orally dissolving tablets (ODTs) help address dysphagia concerns and enhance compliance and adherence.